10. April 2017

Updated health economic analysis Palbociclib

Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.

Matter-Walstra K, Schwenkglenks M, Dedes KJ.

Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4209-5. [Epub ahead of print] No abstract available.

 

Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).

Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ.

Breast Cancer Res Treat. 2016 Jul;158(1):51-7. doi: 10.1007/s10549-016-3822-z. Epub 2016 Jun 8.

Tags: work, cancer
Kommentare: 0

Fr

18

Jun

2021

Sailing 2021

mehr lesen

Fr

16

Apr

2021

Vorbereitungen Rûzje Wyn 2021

Sa

24

Okt

2020

Kroatien 2020

Di

01

Sep

2020

Sailing Croatia 2020

mehr lesen

Sa

23

Mai

2020

Arc-en-ciel

Thanks to Saskia and Patrick for these recordings

mehr lesen

Sa

21

Dez

2019

Newest Publication

Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study.

Panje CM, Putora PM, Hundsberger T, Hottinger AF, Roelcke U, Pesce G, Herrmann E, Matter-Walstra K.

Swiss Med Wkly. 2019 Dec 2;149:w20153. doi: 10.4414/smw.2019.20153. eCollection 2019 Dec 2.